CPT code 0339U: Prostate RNA test, HOXC6 and DLX1 expression2026 Medicare lab fee · Clinical Laboratory Fee Schedule
This urine-based prostate cancer test profiles HOXC6 and DLX1 mRNA to estimate the probability of high-grade disease during evaluation of suspected prostate cancer.
Medicare pays $760.00 for 0339U under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$760.00
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2023
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 7 sections
What 0339U covers
This molecular test measures HOXC6 and DLX1 mRNA expression using reverse-transcription PCR. The specimen is first-void urine collected after a digital rectal examination. An algorithm reports a probability of high-grade prostate cancer. Urologists may order it while evaluating suspected prostate cancer, including when considering whether to proceed with biopsy after an elevated PSA result.
Report 0339U for the test performed on the urine specimen. The Medicare Clinical Laboratory Fee Schedule pays one national amount per code, with no locality or office-versus-facility adjustment. The 2026 national CLFS amount is $760.00, unchanged from 2023 through 2026. Medicare pays this code through the CLFS; there is no physician fee schedule payment or separately payable physician interpretation component for this code.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 0339U
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 0339U. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Not on the physician fee schedule
The physician fee schedule doesn’t list 0339U: Medicare pays the test only from the CLFS.
0339U on the lab fee schedule since 2022
0339U · CLFS 2026 Q4 (current)
$760.00
Unchanged since Jan 1, 2023
Every change on file
- Jan 1, 2023 · CLFS 2023 Q1MAC-priced → $760.00
17 quarterly CLFS releases on file, first CLFS 2022 Q4. A code missing from a quarter wasn’t on that release.
0339U compared with similar tests
- 84153Total PSA$18.39
- Code 84153 reports a prostate-specific antigen test, generally performed on blood. Code 0339U profiles HOXC6 and DLX1 mRNA in post-examination first-void urine and estimates the probability of high-grade cancer.
0339U billing questions
What specimen does this test use?
It uses first-void urine collected after a digital rectal examination and profiles HOXC6 and DLX1 mRNA.
When might a urologist order 0339U?
It may be used when evaluating suspected prostate cancer, including when considering whether to proceed with biopsy after an elevated PSA result. The result estimates the probability of high-grade disease.
Is 0339U the same as a PSA test?
No. 0339U profiles gene expression in urine and estimates the probability of high-grade cancer; a PSA test measures prostate-specific antigen, typically in blood.
Does 0339U include a prostate biopsy?
No. 0339U reports a urine-based molecular test, not tissue sampling or biopsy pathology.
How does Medicare pay 0339U?
Medicare pays it under the CLFS at one national amount per code, without a locality or office-versus-facility adjustment. The code has no separate physician interpretation payment.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 0339U and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist